30% Upside for Leader in Market Growing 30% Annually?
Renowned e-signature company DocuSign, Inc. (NASDAQ:DOCU) has got firmly back on track after some turbulence in 2021 and 2022 when the company’s share price declined by more than 75%.
The recent stock performance has fared much better, begging the question where is the ceiling for this once hot stock? » Read more about: 30% Upside for Leader in Market Growing 30% Annually? »
Read More
Market Commentary: How Charlie Got So Rich
Despite his fame as Warren Buffett’s right-hand man, Charlie Munger, who recently passed away at 99, maintained a remarkably low public profile, letting his vast wisdom and sharp wit speak through his investments and rare, yet profound, public statements.
Charlie was renowned for his role as the vice chairman of Berkshire Hathaway and his partnership with Warren Buffett,
» Read more about: Market Commentary: How Charlie Got So Rich »
Read More
Market Commentary: 1 Food Stock That Defies All Odds
Famously, it’s been said that the restaurant business is a horrible one. You have to pay the rent, the staff, the food costs, and keep the lights on, and when you’re done with all that you have to hope your menu is right, the chefs show up each day, and the customers like the food.
» Read more about: Market Commentary: 1 Food Stock That Defies All Odds »
Read More
Market Commentary: 1 Healthcare Stock You Don’t Want To Miss
It’s no easy feat trying to track down a company that has been so consistent in growing its top line that each and every single quarterly report is accompanied by a declaration of year-over-year growth but that’s precisely the case with Humana over the past half decade.
If you were attempting to identify a perfect stock,
» Read more about: Market Commentary: 1 Healthcare Stock You Don’t Want To Miss »
Read More
Why Charlie Munger Never Sold Costco Stock — Even When It Looked Overvalued
Charlie Munger became famous in the investment world as Warren Buffett’s right-hand man at Berkshire Hathaway and the architect of Berkshire’s philosophy of buying great businesses at fair prices versus the prior mantra of buying good businesses at great prices.
Over a nearly 100-year life, Munger would pass up innumerable investment opportunities, choosing to put money only into the few that truly offered exceptional value.
» Read more about: Why Charlie Munger Never Sold Costco Stock — Even When It Looked Overvalued »
Read MoreThe Burst
It Is Too Late To Buy This Pelosi Stock?
What started out as a fun joke tracking Nancy Pelosi’s trades has turned into somewhat of a cult following. That’s because Pelosi’s portfolio was up as high as 71% this year alone but her short-term market outperformance is mirrored over the long-term with returns that rival those of Buffett.
That led many to speculate whether it was time to go all-in when she bought Palo Alto Networks earlier this year.
» Read more about: It Is Too Late To Buy This Pelosi Stock? »
Read MoreThe Spotlight
Spotlight: AI + Robotics = 4x Growth
Google. Apple. Amazon. Microsoft. They are all investing in AI but one company you probably have not heard about is Symbiotic, a warehousing automation firm that combines advanced robotics with artificial intelligence.
It’s one of those businesses that’s hard to wrap your head around at first but it’s been a huge hit on Wall Street.
» Read more about: Spotlight: AI + Robotics = 4x Growth »
Read MoreThe Daily
Ramco Cements Share Price Target Raised – What Emkay’s Bullish Call Means
Emkay Research has initiated coverage on The Ramco Cements (TRCL) stock with an “ADD” rating and set a target price (TP) of Rs 1,090, valuing the stock at a FY27 estimated EV/EBITDA multiple of 13x.
The brokerage expects strong market consolidation in South India,
» Read more about: Ramco Cements Share Price Target Raised – What Emkay’s Bullish Call Means »